Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. more
Time Frame | MRUS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.29% | -2.12% | -3% |
1-Month Return | -2.52% | -3.42% | -0.73% |
3-Month Return | -15.74% | -11.13% | 2.87% |
6-Month Return | -22.41% | -5.74% | 7.17% |
1-Year Return | 61.71% | 3.97% | 25.31% |
3-Year Return | 40.11% | 1.05% | 28.38% |
5-Year Return | 146.18% | 34.37% | 81.89% |
10-Year Return | 316.83% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.13M | 29.94M | 49.11M | 41.59M | 43.95M | [{"date":"2019-12-31","value":63.4,"profit":true},{"date":"2020-12-31","value":60.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.68,"profit":true},{"date":"2023-12-31","value":89.49,"profit":true}] |
Cost of Revenue | 49.64M | 57.33M | 86.27M | 11.98M | 127.41M | [{"date":"2019-12-31","value":38.96,"profit":true},{"date":"2020-12-31","value":45,"profit":true},{"date":"2021-12-31","value":67.71,"profit":true},{"date":"2022-12-31","value":9.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (18.51M) | (27.39M) | (37.16M) | 29.60M | 43.95M | [{"date":"2019-12-31","value":-42.11,"profit":false},{"date":"2020-12-31","value":-62.33,"profit":false},{"date":"2021-12-31","value":-84.56,"profit":false},{"date":"2022-12-31","value":67.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (59.44%) | (91.48%) | (75.67%) | 71.19% | 100.00% | [{"date":"2019-12-31","value":-59.44,"profit":false},{"date":"2020-12-31","value":-91.48,"profit":false},{"date":"2021-12-31","value":-75.67,"profit":false},{"date":"2022-12-31","value":71.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 89.79M | 105.82M | 139.08M | 201.62M | 200.49M | [{"date":"2019-12-31","value":44.53,"profit":true},{"date":"2020-12-31","value":52.48,"profit":true},{"date":"2021-12-31","value":68.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.44,"profit":true}] |
Operating Income | (58.66M) | (75.88M) | (89.98M) | (160.04M) | (156.55M) | [{"date":"2019-12-31","value":-5865700000,"profit":false},{"date":"2020-12-31","value":-7587800000,"profit":false},{"date":"2021-12-31","value":-8997600000,"profit":false},{"date":"2022-12-31","value":-16003800000,"profit":false},{"date":"2023-12-31","value":-15654700000,"profit":false}] |
Total Non-Operating Income/Expense | 5.59M | (22.60M) | 12.35M | 21.95M | 15.55M | [{"date":"2019-12-31","value":25.47,"profit":true},{"date":"2020-12-31","value":-102.96,"profit":false},{"date":"2021-12-31","value":56.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.84,"profit":true}] |
Pre-Tax Income | (54.96M) | (85.01M) | (66.58M) | (130.24M) | (151.75M) | [{"date":"2019-12-31","value":-5495700000,"profit":false},{"date":"2020-12-31","value":-8501000000,"profit":false},{"date":"2021-12-31","value":-6657700000,"profit":false},{"date":"2022-12-31","value":-13023500000,"profit":false},{"date":"2023-12-31","value":-15174700000,"profit":false}] |
Income Taxes | 194.00K | 503.00K | 239.00K | 959.00K | 3.19M | [{"date":"2019-12-31","value":6.08,"profit":true},{"date":"2020-12-31","value":15.76,"profit":true},{"date":"2021-12-31","value":7.49,"profit":true},{"date":"2022-12-31","value":30.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (55.15M) | (85.51M) | (66.82M) | (131.19M) | (154.94M) | [{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-15493900000,"profit":false}] |
Income From Continuous Operations | (55.15M) | (85.51M) | (66.82M) | (131.19M) | (176.76M) | [{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-17675800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (55.15M) | (85.51M) | (66.82M) | (131.19M) | (154.94M) | [{"date":"2019-12-31","value":-5515100000,"profit":false},{"date":"2020-12-31","value":-8551300000,"profit":false},{"date":"2021-12-31","value":-6681600000,"profit":false},{"date":"2022-12-31","value":-13119400000,"profit":false},{"date":"2023-12-31","value":-15493900000,"profit":false}] |
EPS (Diluted) | (2.04) | (2.86) | (1.72) | (2.90) | (2.99) | [{"date":"2019-12-31","value":-204,"profit":false},{"date":"2020-12-31","value":-286,"profit":false},{"date":"2021-12-31","value":-172,"profit":false},{"date":"2022-12-31","value":-290,"profit":false},{"date":"2023-12-31","value":-299,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MRUS | |
---|---|
Cash Ratio | 7.90 |
Current Ratio | 8.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MRUS | |
---|---|
ROA (LTM) | -21.60% |
ROE (LTM) | -44.60% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MRUS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MRUS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 80.20 |
P/B | 4.10 |
Price/FCF | NM |
EV/R | 62.91 |
EV/Ebitda | NM |
PEG | NM |
Merus BV (MRUS) share price today is $41.85
Yes, Indians can buy shares of Merus BV (MRUS) on Vested. To buy Merus BV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRUS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Merus BV (MRUS) via the Vested app. You can start investing in Merus BV (MRUS) with a minimum investment of $1.
You can invest in shares of Merus BV (MRUS) via Vested in three simple steps:
The 52-week high price of Merus BV (MRUS) is $61.61. The 52-week low price of Merus BV (MRUS) is $27.11.
The price-to-earnings (P/E) ratio of Merus BV (MRUS) is
The price-to-book (P/B) ratio of Merus BV (MRUS) is 4.10
The dividend yield of Merus BV (MRUS) is 0.00%
The market capitalization of Merus BV (MRUS) is $2.88B
The stock symbol (or ticker) of Merus BV is MRUS